In a bid to strengthen its oncology portfolio, Lilly has entered into a definitive agreement to acquire Kelonia Therapeutics in a deal valued at up to US$7 B. The acquisition grants Lilly access to Kelonia’s proprietary in vivo CAR T platform and lead programme KLN 1010, an investigational one time intravenous gene therapy for multiple myeloma. Kelonia’s proprietary technology provides Lilly with a scalable approach to CAR T therapies, potentially transforming cancer treatment by eliminating the complexities of ex vivo manufacturing and pre administration chemotherapy.